Create a narrative

Xeris Biopharma Holdings Community

NasdaqGS:XERS Community

1 Narratives written by author
0 Comments on narratives written by author
5 Fair Values set on narratives written by author

Create a narrative

Xeris Biopharma Holdings

AN

AnalystConsensusTarget

Consensus Narrative from 6 Analysts

Advancing Recorlev, Gvoke And XP-8121 Will Drive Future Demand

Key Takeaways Strategic investments in Recorlev and untapped Gvoke markets may significantly boost long-term revenue, aligning with medical guidelines to meet growing patient demands. Advancements in XP-8121 for hypothyroidism and improved margins could enhance financial health and earnings, transitioning Xeris to sustainable, profitable growth.

US$6.25

FV

19.8% undervalued

22.48%

Revenue growth p.a.

0

0

0

6 days ago